Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss

NCT05176717 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT05176717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05176717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss
Lead sponsor
Laboratoires Thea
Phase
Phase 2/3
Overall status
Terminated
Start date
December 15, 2021
Completion date
August 2, 2022
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

deaf blind, eye diseases, eye diseases, hereditary, eye disorders congenital, retinal disease, retinitis pigmentosa, usher syndrome type 2, vision disorders